Literature DB >> 9116297

11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.

H Döhner1, S Stilgenbauer, M R James, A Benner, T Weilguni, M Bentz, K Fischer, W Hunstein, P Lichter.   

Abstract

Deletions of the long arm of chromosome 11 (11q) are one of the most frequent structural chromosome aberrations in various types of lymphoproliferative disorders. However, in most conventional chromosome banding studies of B-cell chronic lymphocytic leukemia (B-CLL), 11q deletions were not identified as a frequent aberration. The objective of this study was to analyze the frequency and clinical impact of 11q deletions in B-CLL by interphase cytogenetics using fluorescence in situ hybridization (FISH). Mononuclear cells from 214 patients with B-CLL were studied by FISH using the yeast artificial chromosome (YAC) clone 755b11 from chromosome region 11q22.3-q23.1; we previously showed that this clone was contained within a 2- to 3-Mb sized segment of 11q commonly deleted in lymphoproliferative disorders. Forty-three of the 214 (20%) tumors exhibited 11q deletions; 11q deletions were the second most frequent chromosome aberration following 13q14 (RB1 and/or D13S25) deletions (45%); they were more frequent than trisomy 12 (15%) or deletion of 17p (TP53 gene) (10%). Patients with 11q deletions were younger (P = .01) and had more advanced clinical stages (P = .01). 11q deletions were associated with extensive peripheral, abdominal, and mediastinal lymphadenopathy (P < .001). Patients with 11q deletions had a more rapid disease progression as shown by a shorter treatment-free interval (9 months v 43 months; P < .001). The prognostic effect of 11q deletion on survival strongly depended on the age: in patients less than 55 years old, the median survival time was significantly shorter in the deletion group (64 months v 209 months; P < .001), whereas in patients > or = 55 years old there was no significant difference (94 months v 111 months; P = .82). 11q deletions identify a new clinical subset of B-CLL characterized by extensive lymph node involvement. In younger B-CLL patients, this aberration is an important predictor of survival.

Entities:  

Mesh:

Year:  1997        PMID: 9116297

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

1.  Cloning of a lymphatic peptide/histidine transporter.

Authors:  K Sakata; T Yamashita; M Maeda; Y Moriyama; S Shimada; M Tohyama
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

Review 2.  Microarray-based expression profiling of normal and malignant immune cells.

Authors:  Rheem D Medh
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

Review 3.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  A 23-year-old woman with 11q-chronic lymphocytic leukemia.

Authors:  Carlos Eduardo Miguel; Fábio Morato de Oliveira; Sabrina Dias Leite-Cueva; Eduardo Magalhães Rego; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2010-05-04       Impact factor: 3.064

5.  High-level DNA amplifications are common genetic aberrations in B-cell neoplasms.

Authors:  C A Werner; H Döhner; S Joos; L H Trümper; M Baudis; T F Barth; G Ott; P Möller; P Lichter; M Bentz
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

6.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

7.  Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Authors:  Thirunavukkarasu Velusamy; Nallasivam Palanisamy; Shanker Kalyana-Sundaram; Anagh Anant Sahasrabuddhe; Christopher A Maher; Daniel R Robinson; David W Bahler; Timothy T Cornell; Thomas E Wilson; Megan S Lim; Arul M Chinnaiyan; Kojo S J Elenitoba-Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 10.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.